文献速递乳腺技术与安全乳腺X线

放射医疗器械创新:2000年至2015年通过上市前审批途径获得的批准

Radiological Medical Device Innovation: Approvals via the Premarket Approval Pathway From 2000 to 2015.
PubMed 文献 · J Am Coll Radiol · 2017-01-01

本研究利用美国FDA上市前数据库,评估2000年9月1日至2015年8月31日期间通过上市前审批途径获批的放射医疗器械的临床证据。共识别23项III类放射器械批准,其中乳腺影像16项(70%)、计算机辅助检测软件9项(39%)。中位审批时间475天(范围180-1,116天),中位关键试验患者数201例(范围25-3,946例),34项关键试验中26项(76%)存在至少一种方法学偏倚。

要点

  • 乳腺影像器械占批准总数的70%,计算机辅助检测软件占39%
  • 中位关键试验患者数201例(范围25-3,946例),中位审批时间475天(范围180-1,116天)
  • 34项关键试验中26项(76%)存在至少一种方法学偏倚

核心结论

  • 放射器械主要通过多阅片者、多中心研究获得批准,这是评估诊断技术的推荐标准;鉴于放射器械在现代医学中的关键作用,应进一步努力提高导致批准的临床数据的透明度。

研究设计与样本

  • 本研究为对FDA上市前数据库中2000年9月1日至2015年8月31日期间放射器械批准的批判性评估,使用QUADAS工具评估关键试验的方法学质量。
  • 共识别23项III类放射器械批准,其中乳腺影像16项(70%)、计算机辅助检测软件9项(39%)。
  • 21项器械基于多阅片者、多中心研究获批,1项基于随机对照试验,1项基于临床前技术等效试验。
  • 关键试验中位患者数为201例(范围25-3,946例)。

诊断标准与关键数值

  • 中位上市前审批时间为475天(范围180-1,116天)。
  • 34项关键试验中26项(76%)存在至少一种方法学偏倚。
  • 乳腺影像器械的关键试验患者数更多(P = .009)且前瞻性研究更多。
  • 所有模态中,器械批准时间延长与试验质量较弱相关(r = 0.600,P < .001)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The aim of this study was to critically assess the clinical evidence leading to radiologic medical device approvals via the premarket approval pathway from 2000 to 2015.

METHODS: This study used the publically available FDA premarket database for radiologic device approvals over the past 15 years (September 1, 2000, to August 31, 2015). Approval characteristics were collected for each device, and statistical analysis was performed on the data for each pivotal trial. Additionally, methodological quality of the pivotal trial was determined using the Quality Assessment of Diagnostic Accuracy Studies tool.

RESULTS: Twenty-three class III radiologic device approvals were identified, with breast imaging accounting for 16 (70%) and computer-aided detection software accounting for 9 (39%) approvals. The median premarket approval time was 475 days (range, 180-1,116). Twenty-one devices were approved on the basis of multireader, multicenter studies, one on the basis of a randomized controlled trial, and one on the basis of a preclinical technical equivalence trial. The median number of patients per pivotal trial was 201 (range, 25-3,946). Twenty-six of the 34 pivotal trials (76%) had at least one methodologic bias. Breast imaging devices had a greater number of patients per pivotal trial (P = .009) and more prospective studies. With regard to all modalities, increased time to device approval correlated with weaker trial quality (r = 0.600, P < .001).

CONCLUSIONS: Radiologic devices are largely approved by multireader, multicenter studies, the recommended standard for assessing diagnostic technologies. Given that radiologic devices play a key role in modern medicine, further efforts should be made to increase transparency of clinical data leading to approval.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Ghobadi CW, Hayman EL, Finkle JH, et al. Radiological Medical Device Innovation: Approvals via the Premarket Approval Pathway From 2000 to 2015. J Am Coll Radiol. 2017. PMID: 28061962. doi:10.1016/j.jacr.2016.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。